Education
About Us
Working with TipRanks
Follow Us
Guardant Health (GH)
NASDAQ:GH
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.72Last Year’s EPS
-0.84Same Quarter Last Year
Strong Buy
Based on 19 Analysts Ratings
Earnings Call Summary
Earnings Call Date:Apr 30, 2025
|% Change Since: -21.47%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment with strong revenue growth across multiple segments, gross margin improvements, and raised full-year guidance. However, challenges such as high cash burn and limited commercial payer reimbursement for Shield were noted.Company Guidance
During the Guardant Health Q1 2025 earnings call, the company provided guidance for the fiscal year, highlighting several key metrics and strategic initiatives. Guardant Health raised its full-year revenue guidance to a range of $880 million to $890 million, representing approximately 19% to 20% growth compared to 2024. Oncology revenue is expected to grow by about 18% year-over-year, driven by increased volumes and improved ASPs for Guardant360 and Reveal. The Biopharma & Data business is projected to achieve low double-digit growth, while Shield revenue guidance was increased to $40 million to $45 million, up from $25 million to $30 million, due to higher ASPs following ADLT status and increased test volumes. The company anticipates full-year non-GAAP gross margins between 62% and 63%, with a focus on reducing cash burn and achieving cash flow breakeven by 2028.Strong Revenue Growth
Guardant Health reported a 21% year-over-year increase in Q1 revenue, totaling $203.5 million.
Oncology Business Performance
Oncology revenue grew 20% year-over-year to $150.6 million with oncology volume increasing 25% to approximately 59,000 tests.
Gross Margin Improvement
Both Reveal and Shield became gross margin positive in Q1 2025, driven by cost reductions and improved ASPs.
Expansion in Screening with Shield
Shield testing revenue reached $5.7 million in Q1, with approximately 9,000 tests conducted. Shield received ADLT status, increasing Medicare price from $920 to $1,495.
Biopharma & Data Growth
Biopharma & Data revenue grew 21% year-over-year, with strategic collaborations including a new agreement with Pfizer.
Raising Full-Year Revenue Guidance
Guardant Health increased its full-year 2025 revenue guidance to $880 million to $890 million, up from $850 million to $860 million.
GH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2025 | $47.23 | $48.87 | +3.47% |
Feb 20, 2025 | $47.40 | $42.87 | -9.56% |
Nov 06, 2024 | $25.29 | $28.59 | +13.05% |
Aug 07, 2024 | $33.96 | $30.27 | -10.87% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Guardant Health (GH) report earnings?
Guardant Health (GH) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Guardant Health (GH) earnings time?
Guardant Health (GH) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GH EPS forecast?
GH EPS forecast for the fiscal quarter 2025 (Q2) is -0.72.